DailyIQ
Last updated1 minute ago

BDX·Becton, Dickinson and Company

$185.92
+3.01 (+1.65%)
After Hours
High
$186.63
Open
$182.39
Market Cap
49.16B
52W High
$195.19
Low
$181.28
P. Close
$185.92
P/E
52.18
52W Low
$129.65
Fwd P/E
13.76
DailyIQ Est.
$199.01
Inst. Ownership
3.2%
Short Interest
4.03%
Days to Cover
6.1
Technical Score (1D)
50
NEUTRAL
News Sentiment
58
BULLISH
Becton, Dickinson’s first U.S. deployment of the BD Vmax 160 pharmacy automation robot at Fairview Health Services came in the last 2.6 hours, marking a milestone for the company’s automation portfolio. The robot automates specialty and refrigerated medication handling in high‑volume outpatient pharmacies, a capability that addresses the increasing complexity of drug fulfillment. By proving the system in a large health‑system setting, BD signals that it can win similar contracts nationwide, potentially boosting its automation‑related revenue streams over the next 10 trading days. The deployment also demonstrates the scalability of BD’s technology, which could accelerate the rollout of its Vmax line to other U.S. health systems. Watch for BD’s earnings releases and any follow‑up contracts announced by Fairview or other health‑system partners, as these will confirm whether the pilot translates into sustained revenue growth. Additionally, monitor any regulatory updates on pharmacy automation standards, since tighter compliance requirements could either accelerate adoption or create implementation hurdles. Finally, keep an eye on the broader specialty‑pharmacy market, as increased automation may shift competitive dynamics and pricing pressures in the sector.
Earnings Summary
Becton, Dickinson and Company (BDX) is a global medical technology firm that delivers a broad portfolio of medical supplies, devices, and diagnostic solutions across its Medical, Connected Care, BioPharma Systems, and Interventional and Life Sciences segments, positioning it firmly within the medical instruments and supplies sector. In the most recent two quarters, BDX posted revenue of $5.27 billion in Q1 2025 and $5.51 billion in Q2 2025, a year‑over‑year increase of roughly 4.5% and 4.8% respectively, while EPS rose from $3.35 to $3.68, beating analyst estimates in both periods; the company continued this trend into Q3 2025 with revenue of $5.89 billion and EPS of $3.96, again surpassing expectations. The pattern of earnings beats persisted into Q1 2026, where revenue of $5.25 billion fell short of the $5.53 billion estimate but EPS of $2.91 still exceeded the $3.31 forecast, indicating a slight deceleration in revenue growth but sustained profitability. Historically, BDX has maintained a steady YoY revenue growth trajectory of around 4–5% over the past four quarters, with EPS consistently beating estimates in three of the last four quarters, underscoring a resilient earnings profile even when revenue growth moderates. Recent news highlights a FDA recall of Huons sodium chloride ampules, which could temporarily disrupt supply chains and affect cash flow, and the completion of enrollment in the PREVENT trial for Phasix Mesh, a potential long‑term growth catalyst; these developments may influence pricing and reimbursement discussions and could be reflected in the next earnings guidance. Investors should watch for any updates on the recall’s financial impact, the interim data from the PREVENT trial, and any guidance adjustments that may clarify BDX’s near‑term outlook, as these factors will be key to understanding the company’s ability to sustain its earnings momentum in the coming quarter.

EPS

EstBeatMiss
$2.60$2.98$3.37$3.75$4.14Q2'25Q3'25Q1'26Q2'26Q3'26Q4'25
QtrEstActual+/−
Q4'25$2.81 - -
Q3'26$3.17$3.23+1.8%
Q2'26$2.77$2.90+4.5%
Q1'26$3.31$2.91-12.1%
Q3'25$3.91$3.96+1.1%
Q2'25$3.40$3.68+8.2%

Revenue

EstBeatMiss
$4.5B$4.9B$5.3B$5.7B$6.1BQ2'25Q3'25Q1'26Q2'26Q3'26Q4'25
QtrEstActual+/−
Q4'25$5.2B - -
Q3'26$4.9B$5.0B+1.0%
Q2'26$4.7B$4.7B-0.0%
Q1'26$5.5B$5.3B-5.0%
Q3'25 - $5.9B -
Q2'25 - $5.5B -

Market Data

BDX Stock Snapshot

HOLD50/100
$185.73$0.19 (0.1%)
Market cap
49.16B
P/E ratio
52.2
Day range
$181.28 – $186.63
News sentiment
58/100 · Neutral
Analyst target
$195.67 (+5.4%)
Consensus
Hold · 23 analysts
52-week range+43.3% off low · -4.8% from high
$129.65$195.19
Price $185.73 DailyIQ Est. $199.01

BDX sits in the upper part of its 52-week range with the technical picture unresolved. Institutional coverage is thorough here, so shifts in analyst expectations show up in price quickly.

Reverse DCF

What growth is priced into BDX?

CHEAP

At today's price, Becton, Dickinson and Company needs to grow free cash flow about 3.8% a year for the next 10 years to justify its valuation at a 6.59% cost of capital. Over its actual history it has compounded free cash flow at 7.2% a year, so the market is asking for 3.4 percentage points below its own delivered rate. On that basis BDX looks priced below what its own growth record supports.

Implied FCF growth
3.8%
Historical FCF CAGR
7.2%
Growth gap
-3.4 pts
Verdict
CHEAP
Discount rate (WACC)
6.59%
Beta
0.62

Behaviour On Record

What BDX's own history says about today's numbers

Realized volatility (21d)
23.2% 71st pct
Below its peak
-18.2%
vs 200-day average
+15.1%
Up days (1y)
48%

Becton, Dickinson and Company is currently running 23.2% annualised volatility over the last 21 sessions. Measured against BDX's own 13 years of daily returns rather than a market-wide average, that is the 71st percentile a little above its own norm, against a typical reading of 18.8%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

BDX is trading -18.2% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -16.9%, and the deepest was -34.0% in 2025. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits +15.1% from its 200-day moving average. Against every other day in its history, that gap ranks at the 97th percentile a wider gap than this stock usually carries. Over the past year BDX closed higher on 48% of sessions, and it is currently 3 sessions into a rising streak.

On September specifically: over 14 years of records, BDX finished the month higher 2 of 14 times, with a median return of -1.2% and an average of -2.2%. Its strongest month historically has been July at +4.0% on average, its weakest September at -2.2%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: BDX has opened more than 2% away from the prior close in 72 of 3,268 sessions (2.2% of the time), with the largest gaps running +35.8% and -8.9%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 4 dated reports on file, BDX moved an average of 1.9% in the session after earnings, closing higher 2 of those 4 times, with a median move of -0.3% and a largest of -3.6%.

All figures computed from 3,269 daily closes between 2013-09-16 and 2026-09-15, split-adjusted, recomputed daily. Percentiles are against BDX's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of BDX's sector?

Becton, Dickinson and Company sits in the Health Care sector, currently ranked 3rd of 11 GICS sectors by relative-strength rotation score (leading).

Sector rank
#3 of 11
Sector state
Leading
Sector rotation score
80

Options Market

What is the options market pricing for BDX?

CallsPuts

For Becton, Dickinson and Company's nearest expiry (2026-09-18, 3 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.41), with at-the-money implied volatility around 44.2%. The options market is pricing roughly a ±4.5% move by that expiry — a range of about $177.40–$194.06.

Put/call ratio (2026-09-18)
0.41
ATM implied volatility
44.2%
Total open interest
5,164
Expected move by 2026-09-18
±4.5% ($177.40–$194.06)

Analyst Rating Changes

Are analysts turning bullish or bearish on BDX?

B of A Securities most recently reiterated its rating on Becton, Dickinson and Company to Neutral on Aug 31, 2026 with a price target of $200 (from $185). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
B of A SecuritiesNeutral
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Aug 31, 2026B of A SecuritiesMaintainedNeutral$185 → $200
Aug 13, 2026RBC CapitalMaintainedSector Perform$180 → $190
Aug 7, 2026CitigroupMaintainedBuy$198 → $204
Aug 7, 2026RBC CapitalMaintainedSector Perform$175 → $180
Aug 7, 2026Piper SandlerMaintainedNeutral$161 → $175
Aug 7, 2026Wells FargoMaintainedEqual-Weight$161 → $170
Aug 5, 2026TD CowenMaintainedHold$163 → $182
Jul 28, 2026UBSInitiatedBuy$190
Jul 6, 2026Evercore ISI GroupMaintainedOutperform$190 → $180
May 11, 2026BarclaysMaintainedOverweight$202 → $204
May 8, 2026Wells FargoMaintainedEqual-Weight$157 → $161
May 4, 2026TD CowenMaintainedHold$189 → $163

BDX Competitive Positioning

Becton, Dickinson and Company (BDX) is tracked alongside these names in Medical Instruments & Supplies on DailyIQ — ranked by market cap, with today's move alongside.